{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H5N1+vaccine",
    "query": {
      "intervention": "H5N1 vaccine"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 110,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=H5N1+vaccine&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T11:46:27.355Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03283319",
      "title": "Panblok H7 Vaccine Adjuvanted With AS03 or MF59",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "3.75 ug Panblok H7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "7.5 ug Panblok H7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "15 ug Panblok H7",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biomedical Advanced Research and Development Authority",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 366,
      "start_date": "2017-09-20",
      "completion_date": "2018-11-09",
      "has_results": true,
      "last_update_posted_date": "2020-05-06",
      "last_synced_at": "2026-09-23T11:46:27.355Z",
      "location_count": 4,
      "location_summary": "Lenexa, Kansas • Wichita, Kansas • Lexington, Kentucky + 1 more",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03283319"
    },
    {
      "nct_id": "NCT01995695",
      "title": "Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza A Virus, H7N9 Subtype"
      ],
      "interventions": [
        {
          "name": "Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Inactivated subvirion H7N9 influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 48,
      "start_date": "2013-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-07-27",
      "last_synced_at": "2026-09-23T11:46:27.355Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01995695"
    },
    {
      "nct_id": "NCT03701061",
      "title": "Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza A Subtype H5N1 Infection"
      ],
      "interventions": [
        {
          "name": "Seasonal Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 12,
      "start_date": "2018-10-11",
      "completion_date": "2020-01-31",
      "has_results": true,
      "last_update_posted_date": "2020-03-11",
      "last_synced_at": "2026-09-23T11:46:27.355Z",
      "location_count": 1,
      "location_summary": "Decatur, Georgia",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03701061"
    },
    {
      "nct_id": "NCT01236040",
      "title": "Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals' investigational vaccine GSK2590066A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK Biologicals' investigational vaccine GSK2592984A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK Biologicals' investigational vaccine GSK2340274A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK Biologicals' investigational vaccine GSK2340273A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 521,
      "start_date": "2010-11-29",
      "completion_date": "2012-08-20",
      "has_results": false,
      "last_update_posted_date": "2017-05-10",
      "last_synced_at": "2026-09-23T11:46:27.355Z",
      "location_count": 4,
      "location_summary": "Anaheim, California • Stockbridge, Georgia • Lenexa, Kansas + 1 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01236040"
    },
    {
      "nct_id": "NCT01766921",
      "title": "Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pandemic H5N1 Influenza"
      ],
      "interventions": [
        {
          "name": "Adjuvanted H5N1 pandemic influenza vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 1393,
      "start_date": "2013-01",
      "completion_date": "2014-07",
      "has_results": true,
      "last_update_posted_date": "2019-01-30",
      "last_synced_at": "2026-09-23T11:46:27.355Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Hollywood, Florida • Wichita, Kansas + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01766921"
    },
    {
      "nct_id": "NCT03738241",
      "title": "2017 A/H7N9 IIV Revaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Avian Influenza",
        "Influenza Immunisation"
      ],
      "interventions": [
        {
          "name": "A/H7N9",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03",
          "type": "DRUG"
        },
        {
          "name": "Phosphate Buffered Saline (PBS) diluent",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "19 Years to 70 Years"
      },
      "enrollment_count": 304,
      "start_date": "2018-12-18",
      "completion_date": "2020-06-19",
      "has_results": true,
      "last_update_posted_date": "2021-07-30",
      "last_synced_at": "2026-09-23T11:46:27.355Z",
      "location_count": 9,
      "location_summary": "Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03738241"
    },
    {
      "nct_id": "NCT01928472",
      "title": "Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "H7N9 Influenza"
      ],
      "interventions": [
        {
          "name": "H7N9c low dose with adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H7N9c medium dose with adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H7N9c high dose with adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H7N9c high dose without adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 402,
      "start_date": "2013-08",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2019-06-11",
      "last_synced_at": "2026-09-23T11:46:27.355Z",
      "location_count": 6,
      "location_summary": "San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01928472"
    },
    {
      "nct_id": "NCT02957656",
      "title": "Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza A Virus, H7N9 Subtype"
      ],
      "interventions": [
        {
          "name": "H7N9 pLAIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "H7N9 pIIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03 adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "20 Years to 49 Years"
      },
      "enrollment_count": 53,
      "start_date": "2016-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-10-02",
      "last_synced_at": "2026-09-23T11:46:27.355Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02957656"
    },
    {
      "nct_id": "NCT00755703",
      "title": "Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza A Subtype H5N1 Infection"
      ],
      "interventions": [
        {
          "name": "Pandemic Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Altimmune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "19 Years to 49 Years"
      },
      "enrollment_count": 48,
      "start_date": "2008-10",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-09-23T11:46:27.355Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00755703"
    },
    {
      "nct_id": "NCT01658800",
      "title": "Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "VAX161C vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "VaxInnate Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 275,
      "start_date": "2012-09",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-09-23T11:46:27.355Z",
      "location_count": 2,
      "location_summary": "South Miami, Florida • Lenexa, Kansas",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01658800"
    }
  ]
}